Welcome to our dedicated page for 23Andme Holding Co SEC filings (Ticker: ME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for ME (23andMe Holding Co., now Chrome Holding Co.) provides access to the company’s regulatory disclosures, including reports related to its Chapter 11 proceedings and the sale of substantially all of its assets. These documents are central for understanding how the genetics-led consumer healthcare and research business has been restructured and how claims and interests are treated under the proposed plan of reorganization.
Recent Form 8-K filings describe key milestones in the Chapter 11 cases filed in the U.S. Bankruptcy Court for the Eastern District of Missouri. They include disclosures about the company’s entry into debtor-in-possession financing arrangements, court approval of bidding procedures, and the Asset Purchase Agreement with 23andMe Research Institute, a California nonprofit public benefit corporation that agreed to acquire substantially all of the debtors’ assets for a cash purchase price plus assumption of specified liabilities. Subsequent 8-Ks report court approval of the transaction and the closing of the asset sale.
Other 8-K filings outline the name change from 23andMe Holding Co. to Chrome Holding Co., summarize the proposed Chapter 11 plan and related disclosure statement, and describe how different classes of claims and equity interests, including holders of the former holding company’s stock, may be treated if the plan becomes effective. Several filings also include cautionary language noting that trading in the company’s common stock during the Chapter 11 cases is highly speculative and that market prices may not reflect any ultimate recovery for shareholders.
Through Stock Titan, users can review these filings in one place and use AI-powered tools to quickly identify the portions that discuss the Chapter 11 process, the asset sale to 23andMe Research Institute, the handling of telehealth assets such as Lemonaid Health, and the proposed distributions under the plan. Filings such as 10-Q and 10-K, where available, can provide additional background on the company’s historical financial condition, segment reporting, and risk factors leading up to the restructuring.
This page is particularly relevant for those researching ME-related bankruptcy disclosures, asset disposition terms, plan of reorganization details, and the implications for creditors and equity holders. Real-time updates from EDGAR combined with AI-generated highlights can help readers navigate complex legal and financial language in lengthy SEC documents.
Chrome Holding Co., formerly known as 23andMe Holding Co., describes a leadership and compensation update while it remains in Chapter 11 bankruptcy proceedings. The company previously sold substantially all of its assets to 23andMe Research Institute under an Asset Purchase Agreement, and that nonprofit has now appointed Chrome’s interim leader, Joseph Selsavage, as its Chief Financial Officer.
During a defined transition period starting August 21, 2025, Selsavage will serve in a dual role as Chief Executive Officer and Chief Financial and Accounting Officer of Chrome Holding Co. and as Chief Financial Officer of the Research Institute. For his work at Chrome during this time, he will receive 75% of his current annual base salary rate of $600,000. The board’s Special Committee also removed the “Interim” designation from his title, formally naming him Chief Executive Officer and Chief Financial and Accounting Officer.
Joseph Anthony Selsavage, listed at C/O Chrome Holding Co., reported an insider sale on 08/20/2025. The Form 4 shows a Code F disposition of 5,232 shares of Class A Common Stock at $3.70 per share, leaving 86,163 shares beneficially owned. The filing is signed on behalf of Mr. Selsavage by an attorney-in-fact on 08/21/2025. The report indicates the seller is an officer with the title listed as CEO, CFO & CAO.
23andMe Holding Co. (Chrome Holding Co.) filed a Proposed Joint Plan and a Proposed Disclosure Statement in connection with Chapter 11 cases. The Proposed Plan and Disclosure Statement are dated
Chrome Holding Co., formerly known as 23andMe Holding Co., has officially changed its corporate name. Effective August 14, 2025, the company filed a certificate of amendment to its Certificate of Incorporation in Delaware to change its name from “23andMe Holding Co.” to “Chrome Holding Co.”
The company states that this name change does not affect the rights of its stockholders and that no other changes were made to its Certificate of Incorporation. The amendment itself is included as an exhibit to the report for reference.
23andMe Holding Co. (ME) receives Bankruptcy Court approval to sell substantially all assets. On 27 June 2025, the U.S. Bankruptcy Court for the Eastern District of Missouri entered an order authorizing the Debtors to consummate the previously announced Asset Purchase Agreement with TTAM Research Institute, a California non-profit affiliated with co-founder Anne Wojcicki.
Transaction terms: TTAM will purchase virtually all assets—excluding Lemonaid Health’s tele-health operations—for $305.0 million in cash and will assume specified liabilities. TTAM will also act as stalking-horse sponsor to acquire the excluded Lemonaid business for $2.5 million.
Key timeline:
- Chapter 11 petitions filed: 23 March 2025
- Asset Purchase Agreement executed: 13 June 2025
- Court approval of sale: 27 June 2025
- Press release issued: 30 June 2025 (Exhibit 99.1)
The Company reiterates that trading in Class A common stock is highly speculative; market prices may not correspond to any ultimate recovery. No pro-forma financials or creditor recovery estimates were included in this Form 8-K. Stakeholders can access additional documents via Kroll’s restructuring website or hotline.
FAQ
What is the current stock price of 23Andme Holding Co (ME)?
What is the market cap of 23Andme Holding Co (ME)?
